ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
Part of paid clinical trials in Carmel, Indiana.
- Sponsor
- Indiana University
- Study ID
- NCT05879913
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 40 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Coronary CT Angiography (CCTA) — DEVICECoronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
Study Details
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .
Key Dates
- Start date
- Dec 15, 2023
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: CCTA Group
- No Intervention: Usual Care Group
Primary Outcome Measure
Proportion of Atherosclerosis in CCTA Arm [ Time Frame: Baseline ]
Central Contacts
- Elizabeth Rowe(317) 278-1185
- Abhishek Khemka, MD(317) 962-0500
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| IU Health Joe and Shelly Schwarz Cancer Center | Carmel | Indiana | 46032 | Abhishek Khemka, MD (PRINCIPAL_INVESTIGATOR) |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | Indiana | 46202 | Abhishek Khemka, MD (PRINCIPAL_INVESTIGATOR) |
| Methodist Hospital | Indianapolis | Indiana | 46202 | Abhishek Khemka, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Carmel, IN
By condition
By specialty
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyPHASE2 · Recruiting · Astellas Pharma Global Development, Inc. · Anchorage, Alaska
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerPHASE1 · Recruiting · Amgen · Duarte, California
- A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate CancerPHASE1 · Recruiting · Astellas Pharma Global Development, Inc. · Tucson, Arizona